PODD INSULET CORP
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1145197 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY26.5%
TTM net income YoY74.2%
TTM EPS YoY78.4%
Revenue 3-yr CAGR27.0%
Net income 3-yr CAGR52.9%
Margins
Gross margin71.9%
Operating margin18.4%
Net margin13.4%
FCF margin8.2%
EBITDA margin21.7%
Returns
ROE28.9%
ROA13.3%
ROIC (approx.)25.5%
Asset turnover0.99x
Leverage & solvency
Liabilities / assets53.8%
Debt / equity0.61x
Current ratio2.51x
Interest coverage9.91x
Cash quality & payout
Operating cash flow / net income1.19x
Accruals ratio-2.5%
Payout ratio—
Capex / revenue7.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $842.00M | $801.70M | $761.70M | $783.80M | $706.30M | $649.10M | $569.00M | $597.50M |
| Cost of revenue | $209.90M | $239.10M | $232.70M | $215.20M | $196.20M | $196.90M | $159.90M | $166.60M |
| Gross profit | $632.10M | $562.60M | $529.10M | $568.60M | $510.10M | $452.20M | $409.00M | $430.90M |
| R&D expense | $91.60M | $88.10M | $89.70M | $90.90M | $77.20M | $73.40M | $59.60M | $60.60M |
| SG&A expense | $350.70M | $344.80M | $317.20M | $331.40M | $315.20M | $257.70M | $260.70M | $261.00M |
| Operating income | $189.80M | $129.70M | $122.10M | $146.30M | $117.70M | $121.10M | $88.80M | $109.30M |
| Interest expense | $16.20M | $13.50M | $14.70M | $14.90M | $15.60M | $19.60M | $9.20M | $8.70M |
| Pretax income | $177.20M | $118.70M | $113.00M | $140.20M | $122.80M | $28.40M | $48.20M | $111.40M |
| Income tax | $36.10M | $23.70M | $21.90M | $38.50M | $35.20M | $5.90M | $12.70M | $10.60M |
| Net income | $141.10M | $95.00M | $91.10M | $101.60M | $87.60M | $22.50M | $35.40M | $100.70M |
| EBITDA | $218.00M | $156.40M | $148.30M | $170.70M | $139.70M | $143.40M | $110.50M | $130.80M |
| EPS (basic) | 2.03 | 1.37 | 1.30 | — | 1.24 | 0.32 | 0.50 | — |
| EPS (diluted) | 2.03 | 1.37 | 1.30 | — | 1.24 | 0.32 | 0.50 | — |
| Weighted avg. shares (diluted) | 69.49M | 69.40M | 70.20M | — | 70.66M | 70.65M | 74.11M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $584.40M | $534.90M | $480.40M | $716.10M | $757.40M | $1.12B | $1.28B | $953.40M |
| Receivables | $689.00M | $588.70M | $544.70M | $516.90M | — | — | — | — |
| Inventory | $552.10M | $484.80M | $462.50M | $452.60M | $446.30M | $446.90M | $440.80M | $430.40M |
| Current assets | $2.04B | $1.85B | $1.71B | $1.91B | $1.86B | $2.28B | $2.33B | $1.89B |
| PP&E, net | $918.60M | $858.60M | $830.40M | $819.50M | $724.10M | $720.40M | $718.70M | $723.10M |
| Goodwill | $51.60M | $51.60M | $51.60M | $51.60M | $51.60M | $51.70M | $51.50M | $51.50M |
| Intangibles | $114.80M | $115.10M | $115.20M | $117.10M | $105.00M | $102.30M | $99.80M | $98.50M |
| Total assets | $3.42B | $3.17B | $2.99B | $3.19B | $3.03B | $3.47B | $3.52B | $3.09B |
| Current liabilities | $814.40M | $744.20M | $687.50M | $680.10M | $647.70M | $1.01B | $520.40M | $528.40M |
| Short-term debt | $19.10M | $18.90M | $18.60M | $18.40M | $79.90M | $460.70M | $83.10M | $83.80M |
| Long-term debt | $943.00M | $929.50M | $929.50M | $930.80M | $934.90M | $939.00M | $1.61B | $1.30B |
| Total debt | $962.10M | $948.40M | $948.10M | $949.20M | $1.01B | $1.40B | $1.70B | $1.38B |
| Total liabilities | $1.84B | $1.74B | $1.68B | $1.68B | $1.65B | $2.01B | $2.19B | $1.88B |
| Shareholders' equity | $1.58B | $1.42B | $1.30B | $1.52B | $1.38B | $1.46B | $1.33B | $1.21B |
| Net debt | $377.70M | $413.50M | $467.70M | $233.10M | $257.40M | $278.10M | $412.30M | $426.50M |
| Shares outstanding | — | — | — | 70.39M | — | — | 70.36M | 70.20M |
| Cash flow statement | ||||||||
| Operating cash flow | $123.50M | $88.40M | $113.80M | $183.30M | $125.70M | $196.50M | $63.80M | $147.50M |
| Capital expenditure | $57.10M | $32.50M | $24.30M | $135.10M | $25.60M | $18.60M | $12.30M | $53.60M |
| Free cash flow | $66.40M | $55.90M | $89.50M | $48.20M | $100.10M | $177.90M | $51.50M | $93.90M |
| Investing cash flow | -$66.90M | -$37.40M | -$27.70M | -$152.80M | -$31.00M | -$23.20M | -$15.60M | -$68.00M |
| Financing cash flow | -$6.00M | $4.00M | -$319.90M | -$72.50M | -$457.00M | -$343.60M | $277.70M | -$20.90M |
| Depreciation & amortization | $28.20M | $26.70M | $26.20M | $24.40M | $22.00M | $22.30M | $21.70M | $21.50M |
| Stock-based compensation | $20.50M | $19.70M | $21.30M | $20.30M | $16.70M | $7.50M | $18.20M | $20.00M |
| Share buybacks | $0 | $0 | $300.00M | $0 | $29.50M | $30.10M | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.